Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease

<div>Patient’s clinical time course.<i> mPSL</i> methylprednisolone,<i> PSL</i> prednisolone,<i> IVCY</i> intravenous cyclophosphamide, and<i> MTX</i> methotrexate.</div>

Case Reports in Rheumatology

fig3

Figure 3

Figure 3: Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease 